Annotation Detail
Information
- Associated Genes
- BRCA2
- Associated Variants
-
BRCA2 LOSS-OF-FUNCTION
BRCA2 LOSS-OF-FUNCTION - Associated Disease
- pancreatic cancer
- Source Database
- CIViC Evidence
- Description
- Twenty-three patients with pancreatic cancer havoring BRCA1/2 germline mutations received olaparib. Eighteen (78%) patients had a BRCA2 mutation. All but one had received gemcitabine, and 65% had received prior platinum. Tumor response rate was 21.7% and stable disease more than 8 weeks was 35%.
- Variant Origin
- germline
- Variant Origin
- Rare Germline
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/5913
- Gene URL
- https://civic.genome.wustl.edu/links/genes/7
- Variant URL
- https://civic.genome.wustl.edu/links/variants/186
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Pancreatic Cancer
- Evidence Direction
- Supports
- Drug
- Olaparib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 25366685
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Olaparib | Sensitivity | true |